These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 21695609

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I.
    BMJ; 2013 Jul 23; 347():f4678. PubMed ID: 23881948
    [No Abstract] [Full Text] [Related]

  • 3. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF.
    Br J Ophthalmol; 2013 Apr 23; 97(4):454-9. PubMed ID: 23385630
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of neovascular age-related macular degeneration: an unresolved matter].
    Flores-Moreno S, Bautista-Paloma J.
    Arch Soc Esp Oftalmol; 2008 Jul 23; 83(7):405-6. PubMed ID: 18592439
    [No Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG.
    Arch Intern Med; 2012 Jul 09; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC, Brown MM, Rapuano S, Boyer D.
    Am J Ophthalmol; 2020 Oct 09; 218():225-241. PubMed ID: 32565050
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
    Vottonen P, Kankaanpää E.
    Acta Ophthalmol; 2016 Nov 09; 94(7):652-656. PubMed ID: 27481048
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.
    Carneiro AM, Costa R, Falcão MS, Barthelmes D, Mendonça LS, Fonseca SL, Gonçalves R, Gonçalves C, Falcão-Reis FM, Soares R.
    Acta Ophthalmol; 2012 Feb 09; 90(1):e25-30. PubMed ID: 21958440
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
    Jeganathan VS, Verma N.
    Curr Opin Ophthalmol; 2009 May 09; 20(3):223-5. PubMed ID: 19367163
    [Abstract] [Full Text] [Related]

  • 13. [Early treatment of exudative age-related macular degeneration with ranibizumab (Lucentis®): the key to success].
    Matthé E, Sandner D.
    Ophthalmologe; 2011 Mar 09; 108(3):237-43. PubMed ID: 21170652
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.
    Ophthalmology; 2015 Aug 09; 122(8):1569-72. PubMed ID: 26038338
    [Abstract] [Full Text] [Related]

  • 16. Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response.
    Kaiser RS, Gupta OP, Regillo CD, Ho AC, Fineman MS, Vander JF, McNamara JA, Brown GC.
    Ophthalmic Surg Lasers Imaging; 2012 Aug 09; 43(1):13-9. PubMed ID: 21986085
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
    van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS.
    Retina; 2011 Sep 09; 31(8):1449-69. PubMed ID: 21817960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.